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willingness to prescribe long-acting opioids. Two-thirds of the
family physicians were willing to prescribe long-acting opioids
for moderate to severe CNMP. However, attitudinal barriers
exist among those physicians unwilling to prescribe. Educational
interventions should focus on these barriers.
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OBJECTIVES: As a result of safety concerns, labeling for fen-
tanyl patches was strengthened in June 2005 to limit use to
opioid-tolerant patients only. We evaluated prior opioid use in
MHS patients prescribed fentanyl patches to support the DoD
Pharmacy & Therapeutics Committee decision-making process.
METHODS: Study patients included all MHS patients newly
started on fentanyl patch from Jan–Dec 05 (no fentanyl patch
prescription ≤180 days prior to index date). Patients were
assumed to be opioid-tolerant based on prescriptions for a
deﬁned set of opioids considered potentially equipotent to a
starting dose of fentanyl patch (25 mcg/hr) ﬁlled during 45–60
days prior to their index date, or if hospitalized on or during
7–14 days prior to their index date (since opioids might have
been started during hospitalization). We did not estimate cumu-
lative dose or duration of opioids. Duration of “look-back”
periods and the deﬁned set of opioids were varied to provide
information on prescribing patterns. Prescription data were
obtained from DoD’s Prescription Data Transaction Service Data
Warehouse, hospitalization data from the MHS Management
Analysis and Reporting Tool. RESULTS: The percentage of
patients that could not be assumed to be opioid-tolerant prior to
starting fentanyl patch ranged from 27% to 51%; it was most
sensitive to changes in how potentially equipotent opioids were
deﬁned. Results from 3-month periods before (January–March
2005) and after (October–December 2005) labeling changes
were similar. CONCLUSION: The number of MHS patients who
are not opioid-tolerant prior to starting fentanyl patches is
potentially large. Assessments of changes in prescribing behav-
ior following educational efforts are underway. DoD decided in
January 2007 to require prior authorization for fentanyl patches,
based on prior opioid use.
PAIN—Patient-Reported Outcomes
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OBJECTIVES: To assess the sensitivity of the EQ-5D in differ-
entiating between severities of pain related health status (PRHS).
METHODS: Study is being conducted with chronic pain patients
attending a specialty pain centre in Edmonton, Alberta, Canada.
Self reported PRHS was determined using standardized clinical
measures that included the Pain Disability Index and The Facial
Pain Scale. These measures were slightly modiﬁed to facilitate
comprehension based on information generated from pilot
testing. Patients were categorized according to their PRHS and
the EQ-5D was administered to quantify their health utility.
Linear regressions were used to compare health utilities between
severity levels of PHS adjusting for gender, marital status, age,
month as a patient, smoking status and income. RESULTS:
Sixty-four patients have been assessed. The mean utility was
0.5524 (n = 30) for persons with moderate disability and severe
pain (MDSP), 0.3625 (n = 9) for persons with severe disability
and extreme pain (SDEP), 0.3358 (n = 22) for persons with
severe disability and severe pain (SDSP), and 0.2965 (n = 3) for
persons with moderate disability and extreme pain (MDEP).
Compared to persons with MDSP, persons with SDSP were asso-
ciated with a −0.225 utility decrement (p < 0.001), and persons
with SDEP associated with a −0.240 utility decrement (p =
0.002). All other comparisons between PRHS levels were non-
signiﬁcant. CONCLUSION: The EQ-5D may be sensitive in
detecting differences between low and high levels of PRHS but
not within severe levels of PRHS.
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OBJECTIVES: Brief Pain Inventory (BPI) is a self-administered
questionnaire used to assess severity and impact of pain on daily
functions. Developed for use in cancer pain, it is now being
widely used in assessment of both malignant and non-malignant
pain. To date, no published studies exist summarizing BPI’s psy-
chometric properties for both types of pain. The study objective
was to examine the existing evidence of the psychometric prop-
erties of BPI use in patients suffering from either type of pain.
METHODS: A structured literature review was performed to
summarize the psychometric properties of the BPI questionnaire
in both malignant and non-malignant pain. Published papers and
abstracts were retrieved by searching Medline 1983–2006,
SciSearch and pain-related websites. Relevant articles cited from
these search ﬁndings were also reviewed. Key search terms
included: Brief Pain Inventory, reliability, responsiveness and
validity. Articles were included for critical review if psychomet-
ric properties were addressed. RESULTS: Of 202 citations, 22
met inclusion criteria for critical review. Factor analysis 
was used to establish construct validity, which generated 2-items:
intensity and interference. Only one study reported 3-items 
by separating the interference domain by psychological func-
tions/sleep and physical function. Face and content validity were
demonstrated for both types of pain. Studies conducting longi-
tudinal analysis showed BPI scales were sensitive to change and
able to discriminate among groups of patients based on condi-
tion-speciﬁc measures of improvement, no change, or a decline.
Intraclass correlation coefﬁcient for test-retest reliability was
found to range from 0.61–0.76 for pain intensity and 0.81–0.88
for pain interference in malignant- pain. Internal consistency
coefﬁcients were approximately 0.85 for the intensity scale and
0.88 for the interference scale with the Cronbach’s alpha coefﬁ-
cients ranging from 0.77–0.95 for non-malignant pain. CON-
CLUSION: Evidence supports the use of the BPI as a reliable 
and valid pain assessment tool in malignant and non-malignant
pain.
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